ANAB – anaptysbio, inc. (US:NASDAQ)
Stock Stats
News
AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners.
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio [Yahoo! Finance]
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]
Form 8-K/A ANAPTYSBIO, INC For: Apr 20
Form 4/A ANAPTYSBIO, INC For: Apr 20 Filed by: Faga Daniel
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Orwin John A
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Schmid John P.
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: RENTON HOLLINGS
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.